Orforglipron
Aliases: LY3502970
Last verified: 2026-09-23
The short version
The first oral non-peptide GLP-1 receptor agonist — FDA-approved April 2026 as Foundayo for obesity: an Ozempic-in-a-pill without peptide, refrigeration or food/water restrictions. Phase III: up to −12.4% body weight (highest dose, 72 weeks).
Identity & type
- Molecular type
- mali molekul
- Origin
- The first oral non-peptide GLP-1 receptor agonist — FDA-approved April 2026 as Foundayo for obesity: an Ozempic-in-a-pill without peptide, refrigeration or food/water restrictions.
Mechanism of action
Small-molecule GLP-1R agonist (biased toward cAMP).
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. Trials: 3–36 mg/day.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Trials: 3–36 mg/day. Just approved (Foundayo, 2026): expected effects per ATTAIN trials — up to −12.4% weight, pill convenience without food rules; real-world experiences are only now accumulating.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Just approved (Foundayo, 2026): expected effects per ATTAIN trials — up to −12.4% weight, pill convenience without food rules; real-world experiences are only now accumulating.
Protocol — official vs community
Official / label
Investigational oral small-molecule GLP-1 agonist. Phase 3 dosing: once daily oral, fasted, titrated over ~18–24 weeks.
- 01Start 3 mg daily, escalate in 3 mg steps every ≥4 weeks
- 02Maintenance studied at 12–36 mg daily
Duration: Trial-defined.
No injections and no food-timing window beyond the fasted requirement — the main argument for the molecule.
Community (anecdotal)
None — not approved, no legitimate supply.
- Cycle:
- —
- Break:
- —
Anything sold as orforglipron is counterfeit or mislabeled by definition until approval.
Human evidence
Successful ATTAIN Phase III program; FDA approved April 1, 2026 under the accelerated CNPV program — the fastest new-molecule approval since 2002.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Class-typical GLP-1 GI effects.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials